Appendix C Comprehensive Results Optimizing Implementation of Hepatitis C Birth-Cohort Screening and Treatment Strategies: Model-Based Projections Yuankun Li, MS Hao Huang, PhD Zelda B. Zabinsky, PhD Shan Liu*, PhD Industrial & Systems Engineering, University of Washington, Seattle, WA, USA * Corresponding author: Shan Liu, PhD Assistant Professor ISE, Adjunct Assistant Professor Radiology Mechanical Engineering Building, Room G6 Box 352650 Seattle, WA 98195 Office phone: 206-543-7593 Fax: 206-685-3072 Email:
[email protected]
DS1
Appendix C Comprehensive Results
DS2
Table C.1 Optimal Budget Percentages for Strategies 2-4 Birth agecohort
Annual budget percentages allocated to screening every two years
Total number of people treated
Total QALYs (discounted)
Incremental QALYs (discounted) above “do nothing”*
Strategy number
3,466,000
394,000
3,840,505,000
2,384,000
2
Total number of people screened
5 billion dollars per year 40-49
[0,0,0,0,0]
50-59
[0,0,0,0,0]
0
387,000
3,183,543,000
1,663,000
2
60-69
[0,0,0,0,0]
2,215,000
265,000
1,801,670,000
1,115,000
2
1 billion dollars per year 40-49
[0,0,0,0,0]
0
80,000
3,838,291,000
171,000
2
50-59
[0,0,0,0,0]
0
77,000
3,182,059,000
178,000
2
60-69
[0,0,0,0,0]
0
54,000
1,800,717,000
162,000
2
40-49
[0,0,0,0,0]
2,802,000
395,000
3,840,864,000
2,744,000
3
50-59
[0,0,0,0,0]
0
387,000
3,184,555,000
2,674,000
3
60-69
[0,0,0,0,0]
3,294,000
263,000
1,801,855,000
1,300,000
3
40-49
[0,0,0,0,0]
0
80,000
3,838,677,000
557,000
3
50-59
[0,0,0,0,0]
0
77,000
3,182,415,000
535,000
3
60-69
[0,0,0,0,0]
0
54,000
1,800,838,000
283,000
3
5 billion dollars per year
1 billion dollars per year
5 billion dollars per year 40-49
[0.2,0.6,0,0,0]
27,506,000
358,000
3,842,025,000
3,905,000
4
50-59
[0,0.2,0.2,0,0]
15,251,000
356,000
3,186,339,000
4,459,000
4
60-69
[0,0.2,0,0.2,0]
12,509,000
248,000
1,802,297,000
1,742,000
4
1 billion dollars per year 40-49
[0,0,0,0,0]
0
80,000
3,839,336,000
1,216,000
4
50-59
[0,0,0,0,0]
0
77,000
3,182,872,000
992,000
4
60-69
[0,0,0,0,0]
0
54,000
1,800,941,000
386,000
4
*Incremental QALYs is the difference between total QALYs of the optimal solution and the “do nothing” case.
Appendix C Comprehensive Results
DS3
Table C.2 Sensitivity Analysis on Fibrosis Awareness for Strategies 2-4 Birth agecohort
Annual budget percentages allocated to screening every two years
Total number of people treated
Total QALYs (discounted)
Incremental QALYs (discounted) above “do nothing”*
Strategy number
2,118,000
397,000
3,840,381,000
2,260,000
2
Total number of people screened
5 billion dollars per year 40-49
[0,0,0,0,0]
50-59
[0,0,0,0,0]
0
387,000
3,183,469,000
1,588,000
2
60-69
[0,0,0,0,0]
1,872,000
266,000
1,801,606,000
1,051,000
2
1 billion dollars per year 40-49
[0,0,0,0,0]
0
80,000
3,838,292,000
171,000
2
50-59
[0,0,0,0,0]
0
77,000
3,182,056,000
176,000
2
60-69
[0,0,0,0,0]
0
54,000
1,800,701,000
146,000
2
40-49
[0,0,0,0,0]
2,219,000
397,000
3,840,680,000
2,559,000
3
50-59
[0,0,0,0,0]
0
387,000
3,184,355,000
2,475,000
3
60-69
[0.2,0,0,0,0]
9,064,000
259,000
1,801,761,000
1,206,000
3
40-49
[0,0,0,0,0]
0
80,000
3,838,638,000
518,000
3
50-59
[0,0,0,0,0]
0
77,000
3,182,375,000
495,000
3
60-69
[0,0,0,0,0]
0
54,000
1,800,812,000
258,000
3
5 billion dollars per year
1 billion dollars per year
5 billion dollars per year 40-49
[0.6,0,0,0,0]
27,510,000
366,000
3,842,082,000
3,961,000
4
50-59
[0.2,0.2,0,0,0]
17,064,000
356,000
3,186,249,000
4,368,000
4
60-69
[0.2,0,0.2,0,0]
14,092,000
248,000
1,802,269,000
1,714,000
4
1 billion dollars per year 40-49
[0.2,0.4,0,0,0]
6,885,000
71,000
3,839,222,000
1,102,000
4
50-59
[0,0,0,0,0]
0
77,000
3,182,868,000
988,000
4
60-69
[0,0,0,0,0]
0
54,000
1,800,940,000
385,000
4
40-49
[0.2,0.6,0,0,0]
27,506,000
358,000
3,842,000,000
3,880,000
4L
50-59
[0.2,0.2,0,0,0]
17,064,000
356,000
3,186,249,000
4,368,000
4L
60-69
[0.2,0,0.2,0,0]
14,092,000
248,000
1,802,269,000
1,714,000
4L
40-49
[0.2,0.4,0,0,0]
6,885,000
71,000
3,839,222,000
1,102,000
4L
50-59
[0,0,0,0,0]
0
77,000
3,182,868,000
988,000
4L
60-69
[0,0,0,0,0]
0
54,000
1,800,940,000
385,000
4L
5 billion dollars per year
1 billion dollars per year
In strategy 4L, the threshold for the F3 and F4 prevalence in target screening population before switching back to strategy 1 was set lower to study the impact of the threshold values. *Incremental QALYs is the difference between total QALYs of the optimal solution and the “do nothing” case.
Appendix C Comprehensive Results
DS4
Table C.3 Sensitivity Analysis on Larger Budget ($10 Billion/Year) Sensitivity analysis on larger budget
budget percentages allocated to screening every two years
Total number of people screened
Total number of people treated
Total QALYs (discounted)
Incremental QALYs (discounted) above “do nothing”*
Strategy number
10 billion dollars per year 40-49
[0.4,0.2,0,0,0]
27,711,000
760,000
3,844,588,000
6,467,000
1
50-59
[0.2,0.2,0,0,0]
26,387,000
721,000
3,189,682,000
7,801,000
1
60-69
[0.2,0,0.6,0,0]
18,434,000
506,000
1,803,560,000
3,005,000
1
40-49
[0,0,0,0,0]
10,078,000
784,000
3,842,129,000
4,009,000
2
50-59
[0,0,0,0,0]
6,162,000
758,000
3,186,248,000
4,368,000
2
60-69
[0,0,0,0,0]
9,855,000
521,000
1,802,617,000
2,062,000
2
10 billion dollars per year
10 billion dollars per year 40-49
[0.2,0,0,0,0]
25,058,000
771,000
3,842,837,000
4,717,000
3
50-59
[0,0,0,0,0]
6,393,000
757,000
3,187,069,000
5,188,000
3
60-69
[0.2,0,0,0,0]
17,821,000
510,000
1,802,867,000
2,312,000
3
40-49
[0.4,0,0.2,0,0]
27,880,000
752,000
3,844,555,000
6,435,000
4
50-59
[0.2,0.2,0,0,0]
26,387,000
721,000
3,189,682,000
7,801,000
4
60-69
[0.2,0,0.6,0,0]
18,642,000
497,000
1,803,540,000
2,985,000
4
10 billion dollars per year
*Incremental QALYs is the difference between total QALYs of the optimal solution and the “do nothing” case.
